Bausch Health Companies vs Universe Pharmaceuticals
BHC and UPC side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BHC and UPC compare
Bausch Health Companies grew revenue faster over the last twelve months (10.8% versus −22.4% for Universe Pharmaceuticals).
Bausch Health Companies keeps more of each dollar of sales as profit, with a net margin of −7.6% compared with −20.6% at Universe Pharmaceuticals.
Bausch Health Companies scores higher on the StockData Score (8 against 5 for Universe Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BHC | UPC |
|---|---|---|
| Size and price | ||
| Market cap | $3.1B | – |
| Share price | $8.35 | $1.51 |
| Change, 1 year | 20.3% | −59.0% |
| Change, 5 years | −67.9% | −100.0% |
| Beta (5Y) | 1.00 | 1.06 |
| Employees | 20K | 225 |
| StockData Score | ||
| Total score | 8 (better) | 5 |
| Valuation score | 4 (better) | 0 |
| Growth score | 2 | 2 |
| Performance score | 1 | 1 |
| Health score | 1 | 2 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.3× | – |
| EV/EBITDA | 9.3× | – |
| P/FCF | 1.7× | – |
| FCF yield | 59.7% | – |
| Fair value | $37.02 | – |
| Margin of safety | 77.4% | – |
| Growth | ||
| Revenue growth (TTM) | 10.8% (better) | −22.4% |
| Revenue growth, 5Y average | 5.0% | 257% (better) |
| Net income growth (TTM) | −332% | – |
| EPS growth (TTM) | −336% | – |
| Profitability | ||
| Gross margin | – | 35.3% |
| Operating margin | 11.2% (better) | −16.3% |
| Net margin | −7.6% (better) | −20.6% |
| FCF margin | 16.8% (better) | −29.8% |
| Return on equity | – | −7261% |
| Return on invested capital | 5.5% (better) | −78.0% |
| Financial health | ||
| Debt / equity | – | 0.13 |
| Net debt / EBITDA | 7.57 | – |
| Interest coverage | 0.8× (better) | −10.1× |
| Current ratio | 1.56 | 4.05 (better) |
| Altman Z-score | 0.22 | – |
| Piotroski F-score | 6 (better) | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 63.4% | 6.6% |
| Held by insiders | 31.5% | – |
| Insider net buying, 12 months | −$507K | – |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 2.9% | – |
Go deeper
- BHC stock overview
- BHC income statement
- BHC valuation and score
- UPC stock overview
- UPC income statement
- UPC valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.